Papel del tejidoadiposoblanco,marrónyperivascular…
343
62.
Hube F, Birgel M, Lee YM, Hauner H. Expression pattern of tumour necrosis factor
receptors in subcutaneous and omental human adipose tissue: role of obesity and
noninsulin-‐dependent diabetesmellitus. Eur J Clin Invest 1999; 29(8):672–678.
63.
RuanH, LodishHF. Insulinresistance inadipose tissue: direct and indirect effectsof tumor
necrosis factor-‐alpha. CytokineGrowthFactorRev. 2003; 14(5):447–455
64.
Uysal KT, Wiesbrock SM, MarinoMW, Hotamisligil GS. Protection from obesity-‐induced
insulinresistance inmice lackingTNF-‐alpha function. Nature1997; 389:610–614
65.
TakanoM, Nishihara R, Sugano N, Matsumoto K, Yamada Y, TakaneM, et al. The effect of
systemic anti-‐tumor necrosis factor-‐alpha treatment on Porphyromonas gingivalis
infection in type2diabeticmice. ArchOral Biol. 2010; 55(5):379–384
66.
Gómez-‐Hernández A, Otero YF, de las Heras N, Escribano O, Cachofeiro V, Lahera V, et al.
Brown fat lipoatrophy and increased visceral adiposity through a concerted
adipocytokines overexpression induces vascular insulin resistance and dysfunction.
Endocrinology. 2012; 153(3):1242-‐55.
67.
Van Harmelen V, Ariapart P, Hoffstedt J, Lundkvist I, Bringman S, Arner P. Increased
adiposeangiotensinogengeneexpression inhumanobesity. ObesRes. 2000; 8(4):337-‐41.
68.
Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T et al. Enhanced
expression of PAI-‐1 in visceral fat: possible contributor to vascular disease in obesity. Nat
Med. 1996; 2(7):800-‐3.
69.
Jones BH, StandridgeMK, MoustaidN. Angiotensin II increases lipogenesis in 3T3-‐L1 and
humanadiposecells. Endocrinology. 1997; 138(4):1512-‐9.
70.
Gil A, María Aguilera C, Gil-‐Campos M, Cañete R. Altered signalling and gene expression
associatedwith the immune systemand the inflammatory response in obesity. Br J Nutr.
2007; 98Suppl 1:S121-‐6.
71.
Baker RG, Hayden MS, Ghosh S. NF-‐κB, inflammation, andmetabolic disease. Cell Metab.
2011; 13(1):11-‐22.
72.
Chawla A, Nguyen KD, Goh YP. Macrophage-‐mediated inflammation inmetabolic disease.
NatRev Immunol. 2011; 11(11):738-‐49.
73.
Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, Ohsugi M et al. CD8+ effector T
cells contribute to macrophage recruitment and adipose tissue inflammation in obesity.
NatMed2009; 15(8):914–920.
74.
Crandall DL, Hausman GJ, Kral JG. A review of the microcirculation of adipose tissue:
anatomic,metabolic, andangiogenicperspectives.Microcirculation. 1997; 4(2):211-‐32.
75.
Blake GJ, Ridker PM. Inflammatory bio-‐markers and cardiovascular risk prediction. J
InternMed. 2002; 252(4):283-‐94.
76.
Sengenès C, Miranville A, Lolmède K, Curat CA, Bouloumié A. The role of endothelial cells
in inflamedadipose tissue. J InternMed. 2007; 262(4):415-‐21
77.
Cai D, YuanM, Frantz DF, Melendez PA, Hansen L, Lee J, et al. Local and systemic insulin
resistance resulting from hepatic activation of IKK-‐beta and NF-‐kappaB. Nat Med. 2005;
11(2):183-‐90.
78.
Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology. 2006; 43(2
Suppl 1):S54-‐62.
79.
Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;
116(7):1793-‐801.
80.
Mattson MP. Perspective: Does brown fat protect against diseases of aging? Ageing Res
Rev. 2010; 9(1):69-‐76.
81.
Farmer SR. Transcriptional control of adipocyte formation. Cell Metab. 2006; 4 (4):263–
73.
82.
Ishibashi J, SealeP.Medicine. Beigecanbe slimming. Science. 2010; 328(5982):1113-‐4.
83.
Wu J, BoströmP, Sparks LM, Ye L, Choi JH, Giang AH, et al. Beige adipocytes are a distinct
typeof thermogenic fat cell inmouseandhuman. Cell. 2012; 150(2):366-‐76.
84.
Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1-‐α-‐dependent
myokine that drives brown-‐fat-‐like development of white fat and thermogenesis. Nature.
2012; 481(7382):463-‐8.
85.
Ghorbani M, Claus TH, Himms-‐Hagen J. Hypertrophy of brown adipocytes in brown and
white adipose tissues and reversal of diet-‐induced obesity in rats treated with a beta3-‐
adrenoceptor agonist. BiochemPharmacol. 1997; 54(1):121-‐31.
